Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521023 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29384293 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29430340 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL3725103 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29358841 | 1.00 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL31681344 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL31758244 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29528879 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL15405716 | 0.98 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL30532186 | 0.97 | MDM2 (0.41) | MDM2TLR2HDAC3HDAC6MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11149066-B2 | Thrombospondin 1-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-10-19 | — | — | US | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2011-11-17 | — | — | US | disclosed |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2011-11-17 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7795242-B2 | Methods and compositions for immunomodulation | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20050154053-A1 | Methods and compositions for immunomodulation | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149066-B2 | Thrombospondin 1-binding peptide | SERPINC1, TEK, ARGLU1 | MDM2 4184/4885TLR2 2737/4885HDAC3 3101/4885 |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | MDM2 1388/4885TLR2 3444/4885HDAC3 436/4885 |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | MDM2 4684/4885TLR2 1981/4885HDAC3 2179/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | MDM2 4684/4885TLR2 1981/4885HDAC3 2179/4885 |
| US-20240218022-A1 | ANTI-VISTA MACROCYCLIC PEPTIDES AND COMPOSITIONS | VIP, SGTA, NGLY1 | MDM2 2802/4885TLR2 3449/4885HDAC3 1858/4885 |
| US-20050154053-A1 | Methods and compositions for immunomodulation | CD74, CD2, CD4 | MDM2 3543/4885TLR2 234/4885HDAC3 3162/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | MDM2 840/4885TLR2 4853/4885HDAC3 657/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM2 1513/4885TLR2 2904/4885HDAC3 2859/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | MDM2 4665/4885TLR2 1111/4885HDAC3 4245/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | MDM2 1645/4885TLR2 4725/4885HDAC3 451/4885 |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | MDM2 2034/4885TLR2 4377/4885HDAC3 589/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | MDM2 4665/4885TLR2 1111/4885HDAC3 4245/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MDM2 1513/4885TLR2 2904/4885HDAC3 2859/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MDM2 1513/4885TLR2 2904/4885HDAC3 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.